Rigel Pharmaceuticals, Q3 2026 Earnings Call Transcript

Rigel Pharmaceuticals reported record quarterly net product sales of $72.3 million, up 13% year over year, and another profitable quarter. VEPPANU generated $6.6 million in its first six weeks on the U.S. market; the company cited broad early uptake, repeat prescriptions and strong payer access, and sees potential for the drug to become its largest sales contributor. TAVALISSE and REZLIDHIA sales grew, while GAVRETO declined. Rigel expects full-year 2026 revenue of $290 million to $295 million and continues to anticipate positive net income.

The company plans to present updated Phase 1b results for R289 in lower-risk MDS at ASH, complete enrollment and select a dose by year-end, and start a registrational study in 2027. Management sees potential for R289 to address unmet need among previously treated patients and expects to discuss the trial path with the FDA. VEPPANU and R289 are central to Rigel’s growth plans, alongside continued portfolio expansion and financial discipline.